United Laboratories International (HKG:3933) unit The United Bio-Technology (Hengqin)'s investigational new drug applications for UBT48128 tablets were approved by the U.S. Food and Drug Administration (FDA).
The approvals are for the indications of overweight or obesity and type 2 diabetes, according to a Tuesday Hong Kong bourse filing by the pharma company.